Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Google Secures Pentagon AI Deal for Classified Projects 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
HAMPTON, N.J., Feb. 04, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 2:40 p.m. EST in New York City.
The live webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected]
